Tue, May 20, 10:05 AM (35 days ago)
**Apimeds Pharmaceuticals US, Inc. (APUS) Q1 2025 Financial Summary** **Company Overview:** Apimeds Pharmaceuticals US, Inc. (APUS) is a clinical-stage biopharmaceutical company developing Apitox, a bee venom-based toxin for treating inflammatory conditions like osteoarthritis and multiple sclerosis. The company is in the process of obtaining regulatory approvals and securing additional financing. **Financial Performance (Q1 2025 vs. Q1 2024):** - **Revenue:** No revenue generated in either period. - **Net Loss:** Increased by 36% to $402,397 from $296,473. - **Operating Expenses:** - General and administrative expenses rose by 34% to $364,368. - Research and development expenses remained at $0. - **Cash Flow:** - Operating activities used $20,313 in cash, an improvement from $263,100 in the prior year. - Financing activities provided $267,200 in cash, primarily from related-party notes. **Liquidity and Capital Resources:** - **Cash Position:** Increased to $250,342 from $3,455 due to financing activities. - **Accumulated Deficit:** Grew to $4,794,321. - **IPO:** Completed on May 12, 2025, raising $11.9 million in net proceeds. - **Future Operations:** The company believes its cash will be sufficient to fund operations for at least the next twelve months. **Trends and Uncertainties:** - **Operational Losses:** The company expects to continue incurring substantial losses. - **Regulatory Approvals:** Success depends on obtaining necessary approvals and securing additional financing. - **Market Risks:** As a smaller reporting company, APUS has elected not to provide quantitative and qualitative disclosures about market risk. **Future Operations Impact:** - **IPO Proceeds:** Will support current operating plans and potential future developments. - **Related-Party Transactions:** Several notes and advances from related parties were amended, extending maturity dates and impacting cash flow. **Management's Discussion:** - **Financial Condition:** APUS is dependent on obtaining additional financing and achieving profitable operations. - **Results of Operations:** Increased losses were primarily due to higher general and administrative expenses. - **Cash Flows:** Improvements in operating cash flow were offset by increased financing activities. **Conclusion:** APUS faces significant challenges in achieving profitability and securing regulatory approvals. However, the recent IPO provides a financial cushion to support ongoing operations and potential future developments. The company's ability to manage expenses and secure additional financing will be crucial for its long-term success.